Participants in the Series C round include Intermountain Ventures, Regents of the University of Minnesota and the Texas Tech University System, among others, with Scottish Mortgage Investment Trust leading the financing.
The funding will be used to expand Recursion’s AI-enabled drug discovery platform and advance its pre-clinical and clinical treatments for rare diseases. The company, which made one of its 300-gigabyte datasets freely available to researchers and competitors in June, will also continue to grow its drug discovery and development partnerships with other pharmaceutical companies.
More articles about AI:
AI predicts kidney injury in burn victims more quickly, accurately than traditional methods
Memorial Sloan Kettering AI model spots cancer in pathology slides with almost 100 percent accuracy
6 updates in AI ethics: new guidelines, institutes & more
